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Abstract 
Background 
There has been extensive speculation about the relationship between COVID-19 and various 
cardiometabolic and pulmonary conditions. This a complex question: COVID-19 may cause a 
cardiometabolic or respiratory event; admission for a clinical event may result in hospital-acquired 
SARS-CoV-2 infection; both may contribute to a patient surpassing the threshold for presenting to 
services; and the presence of a pandemic may change whether patients present to services at all. To 
inform analysis of these questions, we set out to describe the overall rate of various key clinical 
events over time, and their relationship with COVID-19. 
Methods 
Working on behalf of NHS England, we used data from the OpenSAFELY platform containing data 
from approximately 40% of the population of England. We selected the whole adult population of 
17m patients and within this identified two further mutually exclusive groups: patients who tested 
positive for SARS-CoV-2 in the community; and patients hospitalised with COVID-19. We report 
counts of death, DVT, PE, ischaemic stroke, MI, heart failure, AKI and diabetic ketoacidosis in each 
month between February 2019 and October 2020 within each of: the general population, community 
SARS-CoV-2 cases, and hospitalised patients with COVID-19. Outcome events were defined using 
hospitalisations, GP records and cause of death data. 
Results 
For all outcomes except death there was a lower count of events in April 2020 compared to April 
2019. For most outcomes the minimum count of events was in April 2020, where the decrease 
compared to April 2019 in events ranged from 5.9% (PE) to 40.0% (heart failure). Despite hospitalised 
COVID-19 patients making up just 0.14% of the population in April 2020, these patients accounted for 
an extremely high proportion of cardiometabolic and respiratory events in that month (range of 
proportions 10.3% (DVT) to 33.5% (AKI)).  
Interpretation 
We observed a substantial drop in the incidence of cardiometabolic and pulmonary events in the 
non-COVID-19 general population, but high occurrence of COVID-19 among patients with these 
events. Shortcomings in routine NHS secondary care data, especially around the timing and order of 
events, make causal interpretations challenging. We caution that the intermediate findings reported 
here should be used to inform the design and interpretation of any studies using a general 
population comparator to evaluate the relationship between COVID-19 and other clinical events.  
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Introduction 
High prevalence of cardiometabolic and pulmonary complications has been reported in people with 
COVID-19​1–3​. The relationship between COVID-19 and cardiometabolic or respiratory events is 
complex: COVID-19 may cause a cardiometabolic or respiratory event; admission for a clinical event 
may result in hospital-acquired SARS-CoV-2 infection; both may contribute to admission and 
diagnosis; and the presence of a pandemic may change whether patients present to services at all, as 
evidenced by a substantial drop in the total number of admission for some conditions, such as acute 
coronary syndromes ​4​.  
 
We set out to describe the overall rate of various key clinical events over time, and their relationship 
with COVID-19, using the linked data within OpenSAFELY including detailed primary care records, 
hospital episodes and spells from SUS, and ONS death certificates. Our aim was to provide a broad 
overview of how the rate of recorded outcome events has changed during the pandemic across the 
whole population; and to describe the co-occurrence of COVID-19 and each clinical event, in order to 
inform the design and interpretation of future studies seeking to understand causal relationships 
with COVID-19. 
Methods 
Study design and data sources 
We conducted a time-series study, calculating a​ series of period prevalences, for each month ​. We 
used electronic health record (EHR) data from primary care practices using TPP software linked to 
Office for National Statistics (ONS) death registrations and Secondary Uses Service (SUS) data 
(containing hospital records) through OpenSAFELY. This is a data analysis platform developed during 
the COVID-19 pandemic, on behalf of NHS England, to allow near real-time analysis of 
pseudonymised primary care records at scale, covering approximately 40% of the population in 
England, operating within the EHR vendor’s highly secure data centre. ​5,6​ Details on Information 
Governance for the OpenSAFELY platform can be found in the Appendix. 
Population 
We extracted monthly cohorts containing the whole adult population (age ≥18 years) who were alive 
on the first day of each month (February 2019 to October 2020 inclusive, the months for which there 
was complete data). The population was stratified by presence or absence of a positive SARS-CoV-2 
test result, as well as being hospitalised with COVID-19. All people were in the general population 
group unless they had a positive test for SARS-CoV-2 or were hospitalised with COVID-19. People 
were categorised in the SARS-CoV-2 positive group if they had a positive test in that month, or in any 
previous month. Similarly, people were categorised into the hospitalised with COVID-19 group if they 
were hospitalised with COVID-19 during that month, or in any previous month. If a person both tests 
positive and is hospitalised with COVID-19, then they are categorised into the hospitalised with 
COVID-19 group from the month that the COVID-19 hospitalisation occurs.  
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Outcomes 
We measured eight outcomes: deep vein thrombosis (DVT), pulmonary embolism (PE), ischaemic 
stroke, myocardial infarction (MI), heart failure, acute kidney injury (AKI) and ketoacidosis. Outcomes 
were defined as the presence of a diagnostic code for each of the respective outcomes, either in the 
general practice record, in hospital, or as a cause of death on a death certificate. For AKI and 
ketoacidosis, the outcomes were restricted just to events recorded in hospital or on the death 
certificate. 
Statistical methods 
For each month, we counted the number of patients with each of the relevant outcome events. Each 
person was counted only once each month, but people could appear in multiple months if they have 
repeated records of the outcome. Counts where there were fewer than 5 people in a strata were 
redacted to ensure anonymity. We calculated 95% confidence intervals for the total counts for each 
month. 
Software and reproducibility 
Data management was performed using the OpenSAFELY software, Python 3.8 and SQL, and analysis 
using Python 3.8. All codelists alongside code for data management and analyses can be found at: 
github.com/opensafely/population-outcomes-burden-research ​. All software for the OpenSAFELY 
platform is available for review and re-use at ​github.com/opensafely-core​. 
Results 
The base population was similar across all months, with an average population of 17,595,257 adults. 
The SARS-CoV-2 positive population started at zero before the pandemic, before increasing to 
209,752 people by October 2020. The population hospitalised with COVID-19 reached 32,372 by 
October 2020. 
 
Counts of each outcome per month are presented in Figure 1. All outcomes show a decrease in 
events during the pandemic, with the exception of death, where there was an increase, and 
ketoacidosis, where uncertainty is higher due to the smaller number of events. Full tables containing 
the counts on which Figure 1 is based, as well as figures for the base population can be found at 
github.com/opensafely/population-outcomes-burden-research/tree/master/released_output​. 
 
During the peak of the first wave of the pandemic, in April 2020, total deaths increased by 73.4% 
compared to a year earlier (April 2019), while totals for all other outcomes decreased by between 
5.9% and 40.0%. Full counts and changes are in Table 1. Counting only events that occured in 
patients without a record of SARS-CoV-2 infection or hospitalisation with COVID-19, then reductions 
are greater still. 
 
The population of patients hospitalised with COVID-19 was 0.14% of the total population in April 
2020, rising to 0.18% by October 2020. Hospitalised COVID-19 patients are dramatically 
overrepresented in the population of patients who had outcome events, gIven that the proportion of 
events occuring in this population ranges from 10.3% to 33.5%. 
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Figure 1: Counts of people with adverse events in the whole population. Coloured strata in each column 
represent the general population (blue), those testing positive for SARS-CoV-2 in that month or any time before 
(yellow), and those hospitalised with COVID-19 during that month or any time before (orange). Error bars 
represent 95% confidence intervals. Note that the number of events for each condition (on the y-axis scale) 
varies substantially. 
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Table 1: Changes in counts of events between April 2019 and April 2020, as well as the proportion of events 




Our study has two key findings that are superficially in conflict with each other: a range of key 
cardiometabolic and respiratory events were substantially more common in patients who also had 
COVID-19; however the incidence of these conditions in the whole population overall fell 
substantially during the peak of the COVID-19 pandemic in early 2020, with the reduction in event 
rates varying between 5.9% and 40% for different outcomes. The proportion of cardiometabolic and 
respiratory events where the patient was also hospitalised with COVID-19 varied between 10.3 and 
33.5%. 
Strengths and limitations 
A key strength of our analysis is size: our analysis is based on the detailed primary care and summary 
hospital records of over 17 million people. Our aim was to give a high level overview of how the 
volume of events changed during the pandemic, and the co-occurrence of COVID-19 and each event: 
although we observed a high proportion of events within the COVID-19 population, we did not design 
the study to demonstrate a causal link between the two. Such relationships are likely to be complex: 
for example, some patients may be admitted with a cardiometabolic or respiratory event, and then 
acquire COVID-19 within hospital; some patients may develop COVID-19 and then experience a 
cardiometabolic or respiratory event as a consequence; some patients may have both COVID-19 and 
a cardiometabolic or respiratory event in the community, with both contributing to their 
presentation to services. We did not aim to determine the order that events occurred in: however in 
many cases the order of events cannot be reliably ascertained from the data available at national 
 Total change between April 
2019 and April 2020, 
absolute change (%) 
General population change 
between April 2019 and April 
2020, absolute change (%) 
% of events within 
the hospitalised with 
COVID-19 population 
in April 2020 
Deaths 10,873 (73.4) 3,612 (24.4) 24.4 
Deep vein thrombosis -904 (-29.0) -1,147 (-36.9) 10.3 
Pulmonary embolism -180 (-5.9) -917 (-30.1) 24.9 
Stroke -508 (-8.2) -1,415 (-23.0) 14.8 
Myocardial infarction -1,386 (-28.3) -1,770 (-36.1) 10.5 
Heart failure -11,194 (-40.0) -14,135 (-50.5) 16.8 
Acute kidney injury -2,242 (-15.2) -6,474 (-44.0) 33.5 
Ketoacidosis -56 (-8.5) -213 (-32.2) 26.0 
 . CC-BY 4.0 International licenseIt is made available under a 
perpetuity. 
 is the author/funder, who has granted medRxiv a license to display the preprint in(which was not certified by peer review)preprint 
The copyright holder for thisthis version posted February 19, 2021. ; https://doi.org/10.1101/2021.02.17.21251812doi: medRxiv preprint 
level, such as SUS or HES data, combined with SGSS test date data. For example it is not possible to 
reliably determine the time course or order of events within a hospital spell.  
Findings in context 
A previous study using in-hospital records reported a 40% reduction in the incidence of acute 
coronary syndromes during the peak of Wave 1 of the pandemic in England, consistent with our 
findings, but did not explore co-occurrence with COVID-19​4​. Our definition of myocardial infarction 
was similar, but also measured events recorded in the community and on death certificates: we 
report a 28.3% reduction in events. A recent preprint using detailed COVID-19 Clinical Information 
Network/International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) data 
alongside sparse SUS/HES data estimated that 20-25% of SARS-CoV-2 infections were 
hospital-acquired during the first wave of the pandemic in England ​7​.  
Implications and future research 
Our results suggest the SARS-CoV-2 pandemic is affecting incidence and recording of events in a 
variety of ways. COVID-19 appears to be strongly associated with various cardiometabolic and 
respiratory events; but the rate of those events fell very substantially during the peak of the first 
wave of COVID-19. The reduction in these cardiometabolic and respiratory events across the 
population may be driven by a range of factors: patients may have been reluctant to present to 
services with cardiometabolic and respiratory events due to fear of infection during the peak of the 
pandemic; or there may have been a true reduction in incidence of those events, perhaps caused by 
a change in exposure to risk factors such as air pollution or strenuous activity; or multiple factors may 
have combined to produce the reduction in presentations. Competing risk of death is also likely to be 
important, as many of those who died from COVID-19 would also be at high risk of the measured 
outcomes.  
 
We therefore present this intermediate data for the wider community to inform study designs and 
further analyses by our group and others. We suggest two immediate future directions: firstly, more 
complex analyses of existing national data, consisting of detailed primary care data, and sparse 
secondary care data such as SUS and HES where the timing and order of events is unclear; secondly, 
further analysis of timing and order of events in richer datasets covering a smaller population, such 
as that managed by ISARIC ​8​, ​or other bespoke data collections ​.​ We caution that the intermediate 
findings reported here should be used to inform the design and interpretation of any studies using a 
general population comparator to measure the relationship between COVID-19 and other clinical 
events.  The uncertainties identified in the data, and the results, both highlight the need for greater 
granularity of data related to details and timing of health events occuring in hospital. 
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Appendix 
Information governance and ethics 
NHS England is the data controller; TPP is the data processor; and the key researchers on 
OpenSAFELY are acting on behalf of NHS England. OpenSAFELY is hosted within the TPP environment 
which is accredited to the ISO 27001 information security standard and is NHS IG Toolkit 
compliant;​9,10​ patient data are pseudonymised for analysis and linkage using industry standard 
cryptographic hashing techniques; all pseudonymised datasets transmitted for linkage onto 
OpenSAFELY are encrypted; access to the platform is via a virtual private network (VPN) connection, 
restricted to a small group of researchers who hold contracts with NHS England and only access the 
platform to initiate database queries and statistical models. Pseudonymised structured data include 
demographics, medications prescribed from primary care, diagnoses, and laboratory measures. No 
free text data are included. All database activity is logged; only aggregate statistical outputs leave the 
platform environment following best practice for anonymisation of results such as statistical 
disclosure control for low cell counts. ​11​ The OpenSAFELY research platform adheres to the obligations 
of the UK General Data Protection Regulation (GDPR) and the Data Protection Act 2018. In March 
2020, the Secretary of State for Health and Social Care used powers under the UK Health Service 
(Control of Patient Information) Regulations 2002 (COPI) to require organisations to process 
confidential patient information for the purposes of protecting public health, providing healthcare 
services to the public and monitoring and managing the COVID-19 outbreak and incidents of 
exposure;  this sets aside the requirement for patient consent. ​12​ Taken together, these provide the 
legal bases to link patient datasets on the OpenSAFELY platform. GP practices, from which the 
primary care data are obtained, are required to share relevant health information to support the 
public health response to the pandemic, and have been informed of the OpenSAFELY analytics 
platform. This study was approved by the Health Research Authority (REC reference 20/LO/0651) and 
by the LSHTM Ethics Board (ref 21863). 
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